Jonathan Romeo, DO
Allergy & Immunology · Raleigh, NCNPI 1821250283
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $200,700 of the $230,174 with a category attached, or 87.2%. AstraZeneca accounts for 82.9% of it on its own, with 27 other manufacturers making up the rest. Among allergy & immunology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 574 payments — averaging $401.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$191K
- Optinose US, Inc.$29K
- AbbVie$2K
- Genentech USA, Inc.$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $4K from 22 others
Across 4 payments — averaging $12,419 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$50K
What the payments were for
- Consulting fees$6,5383%
- Speaking & faculty fees$200,70087%
- Grants$1,0000%
- Travel & lodging$4,7832%
- Food & beverage$16,9547%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 254 | $190,922 |
| Optinose US, Inc. | 46 | $29,416 |
| AbbVie | 10 | $2,274 |
| Genentech USA, Inc. | 9 | $1,546 |
| Sanofi | 14 | $1,343 |
| Regeneron Healthcare Solutions, Inc. | 50 | $1,003 |
| Amgen | 90 | $913 |
| GSK | 24 | $429 |
| Aimmune Therapeutics, Inc. | 4 | $381 |
| Novartis | 9 | $350 |
| Pfizer | 14 | $270 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $255 |
| CSL Behring | 7 | $183 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $148 |
| Biocryst US Sales Co., LLC | 5 | $142 |
| Grifols USA, LLC | 5 | $118 |
| Kaleo, Inc. | 6 | $99 |
| Genentech, Inc. | 1 | $82 |
| Galderma Laboratories, L.p. | 1 | $63 |
| Organon | 3 | $59 |
| Sanofi-aventis U.S. LLC | 1 | $46 |
| Lilly USA, LLC | 2 | $38 |
| Shire North American Group Inc | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Alk-abello, Inc | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$230,174 in reported general payments places this provider in the 90th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 29 | $165,310 |
| XolairOmalizumab | 39 | $118,984 |
| Dupixent PenDupilumab | 17 | $66,144 |
| TezspireTezepelumab-Ekko | 11 | $45,164 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $13,036 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,605 |
| Spiriva RespimatTiotropium Bromide | 13 | $7,199 |
| Epinephrine | 34 | $7,113 |
| DuleraMometasone/Formoterol | 17 | $6,430 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,433 |
| Ipratropium Bromide | 51 | $1,266 |
| Azelastine Hcl | 22 | $1,158 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,029 |
| Famotidine | 19 | $422 |
| Montelukast Sodium | 39 | $186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $183 | $165,31029 claims |
| Genentech, Inc.Xolair | $82 | $118,98439 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $190,922 | $63,63349 claims |
| GSKBreo Ellipta | $429 | $9,60516 claims |
| Hikma Pharmaceuticals USAEpinephrine | $13 | $7,11334 claims |
| MerckDulera | $12 | $6,43017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Raleigh
- Karen DunnRaleigh$258K
- Laurie McWilliamsRaleigh$85K
- Sonia BainsRaleigh$23K
- Gurvinder DeogunRaleigh$14K
- Craig LaforceRaleigh$14K
- Maureen PetersenRaleigh$13K
- Heather GutekunstRaleigh$12K
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.